Metamark has previously announced in-network agreements with additional large Blue Cross and Blue Shield Plans and also has agreements in place with the largest PPO networks in the country.
Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, and kidney cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.
For more information, please visit the company's website: www.metamarkgenetics.com.
Metamark® is a registered trademark of Metamark Genetics, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/metamark-announces-agreement-with-blue-cross-and-blue-shield-of-texas-300296595.html
SOURCE Metamark Genetics, Inc.